Oc-459 clinical trials
Also written OC000459.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses oc-459 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 2 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Oxagen Ltd (6) · Atopix Therapeutics, Ltd. (2) · Imperial College London (1) · Chiesi Farmaceutici S.p.A. (1)
Studies
Open first, then newest update. How each study uses oc-459 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Effect of OC459 on the Response to Rhinovirus Challenge in AsthmaCompletedPhase 2Imperial College LondonNCT02660489Written as OC459
- Effect of OC000459 on Eosinophilic Airway Inflammation in Severe AsthmaCompletedPhase 2Chiesi Farmaceutici S.p.A.NCT02560610Written as OC000459
- Effect of OC000459 on Moderate to Severe Atopic DermatitisCompletedPhase 2Atopix Therapeutics, Ltd.NCT02002208Written as OC000459
- Evaluation of Metabolic Profile of OC000459CompletedPhase 1Atopix Therapeutics, Ltd.NCT02341521Written as OC000459
- Proof of Concept Study of OC000459 in Eosinophilic EsophagitisCompletedPhase 2Oxagen LtdNCT01056783Written as OC000459
- A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic RhinitisCompletedPhase 2Oxagen LtdNCT01448902Written as OC000459
- Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4CompletedPhase 1Oxagen LtdNCT01056575Written as OC000459
- Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic SubjectsCompletedPhase 2Oxagen LtdNCT01057927Written as OC000459
- OC000459 Bronchial Allergen ChallengeCompletedPhase 2Oxagen LtdNCT01056692Written as OC000459
- OC000459 Dose Finding Study in Hay Fever Sufferers.CompletedPhase 2Oxagen LtdNCT00697281Written as OC000459
Codes
What other systems call oc-459 · ClinicalTrials.gg INT006020
- UNII (FDA) 04XB9TB8OLTIMAPIPRANTConfirmed FDA, Wikidata
- Wikidata Q27247701oc-459Confirmed FDA, Wikidata
- DrugBank DB11900One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 04XB9TB8OL | TIMAPIPRANT | Confirmed FDA, Wikidata |
| Wikidata | Q27247701 | oc-459 | Confirmed FDA, Wikidata |
| DrugBank | DB11900 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.